• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Eisai selling off Oncology products

Quote
Anonymous said:
Eisai, at the very least, is looking to sell off Ontak(and probably Targretin). I’m no longer at the company but the BD guys at my current company have asked me on several occasions over the last few months about Ontak and flat out told me Eisai is shopping it around.
Click to expand...

Unless your guys are dumber than Eisai's, your guys wouldn't buy Ontak. Ontak and Targretin are not good products but neglected, they are dogs. Eisai was tricked by Ligand. Nobody other than Eisai is that stupid.
 




Anonymous said:
Unless your guys are dumber than Eisai's, your guys wouldn't buy Ontak. Ontak and Targretin are not good products but neglected, they are dogs. Eisai was tricked by Ligand. Nobody other than Eisai is that stupid.
Click to expand...

You really should do some research before you say something this dumb. You def. must be home office. Targretin is Eisai's most profitable drug. Ontak, if sold off of the compendium listing, is almost as profitable. The problem is that Eisai does not understand, nor have the intellectual capital to know how to properly market/ sell these drugs. There is substantial profit to be made, and if a small start-up who knows what they are doing gets either or both of these, it will be very successful.
 




Anonymous said:
Unless your guys are dumber than Eisai's, your guys wouldn't buy Ontak. Ontak and Targretin are not good products but neglected, they are dogs. Eisai was tricked by Ligand. Nobody other than Eisai is that stupid.
Click to expand...

Ligand was and is still one of the most respected drug development companies in the industry. They didn’t trick anyone into buying the drugs. They simple did not want to operate as a sales and marketing organization. They wanted to stick to what they did best and that is drug development. You really should learn your history and up your knowledge base before you spew such stupid statements.

What Eisai was guilty of then (as they are today) is an utter lack of understanding and knowledge of the oncology space, and approached with a very mass market/primary care mentality. There will absolutely be buyers for Ontak and Targretin.

Just to give you a bit of history. When Ligand hired for the launch of Ontak it was one of the hottest most sought after oncology jobs back then. You never met any of them as they almost all left Ligand before the Eisai purchase, and they all landed in much better places than the likes of Eisai…
 




Anonymous said:
Ligand was and is still one of the most respected drug development companies in the industry. They didn’t trick anyone into buying the drugs. They simple did not want to operate as a sales and marketing organization. They wanted to stick to what they did best and that is drug development. You really should learn your history and up your knowledge base before you spew such stupid statements.

What Eisai was guilty of then (as they are today) is an utter lack of understanding and knowledge of the oncology space, and approached with a very mass market/primary care mentality. There will absolutely be buyers for Ontak and Targretin.

Just to give you a bit of history. When Ligand hired for the launch of Ontak it was one of the hottest most sought after oncology jobs back then. You never met any of them as they almost all left Ligand before the Eisai purchase, and they all landed in much better places than the likes of Eisai…
Click to expand...

Ligand was one of the most sought after oncology jobs? Really? What a bunch of self-aggrandizing bs. Oh, and you must be one of those so called oncology "experts" that was "selected" back then, right? LMAO.
 




Anonymous said:
Ligand was and is still one of the most respected drug development companies in the industry. They didn’t trick anyone into buying the drugs. They simple did not want to operate as a sales and marketing organization. They wanted to stick to what they did best and that is drug development. You really should learn your history and up your knowledge base before you spew such stupid statements.

What Eisai was guilty of then (as they are today) is an utter lack of understanding and knowledge of the oncology space, and approached with a very mass market/primary care mentality. There will absolutely be buyers for Ontak and Targretin.

Just to give you a bit of history. When Ligand hired for the launch of Ontak it was one of the hottest most sought after oncology jobs back then. You never met any of them as they almost all left Ligand before the Eisai purchase, and they all landed in much better places than the likes of Eisai…
Click to expand...

Do you live in a land of multi-colored unicorns, candy canes growing like trees, and pots of gold at the end of rainbows? Your post is such BS and incorrect it's not worth picking apart.
 




Anonymous said:
Do you live in a land of multi-colored unicorns, candy canes growing like trees, and pots of gold at the end of rainbows? Your post is such BS and incorrect it's not worth picking apart.
Click to expand...

Oh really? Do tell me where I am inaccurate. This was 1999 and pre Avastin Genentech. Almost all of us came from selling traditional chemo and targeted therapies was the future so not sure how you would disagree with that. Also just look at Ligand’s pipeline and who they are developing with. Eisai would die to have that pipeline.

So once again you prove your greenness in this industry with you moronic statements. Keep in coming as you will look more idiotic with each subsequent post…
 




Anonymous said:
Ligand was one of the most sought after oncology jobs? Really? What a bunch of self-aggrandizing bs. Oh, and you must be one of those so called oncology "experts" that was "selected" back then, right? LMAO.
Click to expand...

Why rewrite the post as it applies equally to you as well…

Oh really? Do tell me where I am inaccurate. This was 1999 and pre Avastin Genentech. Almost all of us came from selling traditional chemo and targeted therapies was the future so not sure how you would disagree with that. Also just look at Ligand’s pipeline and who they are developing with. Eisai would die to have that pipeline.

So once again you prove your greenness in this industry with you moronic statements. Keep in coming as you will look more idiotic with each subsequent post…

I don’t know if 17 years of oncology experience makes me an expert, but you Eisai “oncology” people have to be the most insecure infants in the industry.
 




Anonymous said:
Why rewrite the post as it applies equally to you as well…

Oh really? Do tell me where I am inaccurate. This was 1999 and pre Avastin Genentech. Almost all of us came from selling traditional chemo and targeted therapies was the future so not sure how you would disagree with that. Also just look at Ligand’s pipeline and who they are developing with. Eisai would die to have that pipeline.

So once again you prove your greenness in this industry with you moronic statements. Keep in coming as you will look more idiotic with each subsequent post…

I don’t know if 17 years of oncology experience makes me an expert, but you Eisai “oncology” people have to be the most insecure infants in the industry.
Click to expand...

I can tell you are bitter, the 17 years of experience doesn't get you anywhere but complain on cafepharma. So much experience.!
 




















Anonymous said:
You really should do some research before you say something this dumb. You def. must be home office. Targretin is Eisai's most profitable drug. Ontak, if sold off of the compendium listing, is almost as profitable. The problem is that Eisai does not understand, nor have the intellectual capital to know how to properly market/ sell these drugs. There is substantial profit to be made, and if a small start-up who knows what they are doing gets either or both of these, it will be very successful.
Click to expand...

You must be one of the best people assets Eisai acquired from Ligand. Targretin, Profitable? Do you know the internal rate of return? Eisai didn't develop Targretin nor Ontak, how could Eisai recoup the $$$ (More than $100 Millions) paid for the products and the most valuable human assets? I bet Eisai hasn't recoup all the investment for all the Ligand parts it bought.

Moreover, Targertin could never achived scale of economy, how do you claim it is the most profitable product for Eisai? Do you know how many pennies to product a Aciphex pill or Aricept? Hint: It only costs Pfizer a penny to produce one tablet of Liptor. LOL
 








Anonymous said:
Why rewrite the post as it applies equally to you as well…

Oh really? Do tell me where I am inaccurate. This was 1999 and pre Avastin Genentech. Almost all of us came from selling traditional chemo and targeted therapies was the future so not sure how you would disagree with that. Also just look at Ligand’s pipeline and who they are developing with. Eisai would die to have that pipeline.

So once again you prove your greenness in this industry with you moronic statements. Keep in coming as you will look more idiotic with each subsequent post…

I don’t know if 17 years of oncology experience makes me an expert, but you Eisai “oncology” people have to be the most insecure infants in the industry.
Click to expand...

You must be a typical disgruntled and stupid sales rep, who could never get promoted. I know the species very well. You display all the typical symptoms, including aggrandizing their so called "oncology experience" when it has only been in sales, and with subpar organizations. "Pre-Avastin Genentech"........hmmmmm.......tell me genius, was Avastin the first targeted therapy Gententech launched?
 




Anonymous said:
You must be a typical disgruntled and stupid sales rep, who could never get promoted. I know the species very well. You display all the typical symptoms, including aggrandizing their so called "oncology experience" when it has only been in sales, and with subpar organizations. "Pre-Avastin Genentech"........hmmmmm.......tell me genius, was Avastin the first targeted therapy Gententech launched?
Click to expand...

Yeah and I know your species well too. Primary care hack who knows not of what they speak. No Avastin was not DNA’s first drug, but it was not until the Avastin launch that DNA had a major expansion. So back in 1999, when there were probably half the oncology jobs there are today, Ontak was a very innovative drug that had a lot of promise, not to mention Targretin who most researchers thought would be a lung cancer drug. I had one of the leading sites in the country with the Targretin lung trial and they all thought it would get an approval. Not to mention that Ligand was a great, laidback company to work for and paid right in line with the DNA’s of the world at that time. Not sure why you are trying to make this a fight. All I said was that Ontak and Ligand back in 1999 were very hot products and a hot company. My guess is that in 1999 you were sampling birth control pills or antibiotics or in college/HS, and you have no idea of the history.

Seriously how insecure are you that when anyone who as any level of experience or insight threatens you so you lash out…what a loser you are…
 








Anonymous said:
Yeah and I know your species well too. Primary care hack who knows not of what they speak. No Avastin was not DNA’s first drug, but it was not until the Avastin launch that DNA had a major expansion. So back in 1999, when there were probably half the oncology jobs there are today, Ontak was a very innovative drug that had a lot of promise, not to mention Targretin who most researchers thought would be a lung cancer drug. I had one of the leading sites in the country with the Targretin lung trial and they all thought it would get an approval. Not to mention that Ligand was a great, laidback company to work for and paid right in line with the DNA’s of the world at that time. Not sure why you are trying to make this a fight. All I said was that Ontak and Ligand back in 1999 were very hot products and a hot company. My guess is that in 1999 you were sampling birth control pills or antibiotics or in college/HS, and you have no idea of the history.

Seriously how insecure are you that when anyone who as any level of experience or insight threatens you so you lash out…what a loser you are…
Click to expand...

Well said. Also you have to love how not one of the things you posted have been disputed. Just personal attacks. But isn’t that what ignorant people do? Never address the points made just call people names…
 




Anonymous said:
Yeah and I know your species well too. Primary care hack who knows not of what they speak. No Avastin was not DNA’s first drug, but it was not until the Avastin launch that DNA had a major expansion. So back in 1999, when there were probably half the oncology jobs there are today, Ontak was a very innovative drug that had a lot of promise, not to mention Targretin who most researchers thought would be a lung cancer drug. I had one of the leading sites in the country with the Targretin lung trial and they all thought it would get an approval. Not to mention that Ligand was a great, laidback company to work for and paid right in line with the DNA’s of the world at that time. Not sure why you are trying to make this a fight. All I said was that Ontak and Ligand back in 1999 were very hot products and a hot company. My guess is that in 1999 you were sampling birth control pills or antibiotics or in college/HS, and you have no idea of the history.

Seriously how insecure are you that when anyone who as any level of experience or insight threatens you so you lash out…what a loser you are…
Click to expand...


Many drugs had bright potentials; but the clinical trials didn't deliver. That is part of the pharma business. back in 1999, Pfizer was hot and great company. Time has changed.
 




Top Bottom
Back
Quote